REMASTER Trademark

Trademark Overview


On Tuesday, January 7, 2025, a trademark application was filed for REMASTER with the United States Patent and Trademark Office. The USPTO has given the REMASTER trademark a serial number of 98941335. The federal status of this trademark filing is RESPONSE AFTER NON-FINAL ACTION - ENTERED as of Tuesday, September 9, 2025. This trademark is owned by Remix Therapeutics, Inc.. The REMASTER trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

Pharmaceutical preparations and therapeutic pharmaceutical preparations both for the treatment of cancer, treatment of immune system related diseases and disorders, treatment of cardiovascular diseases and disorders, treatment of genetic diseases and disorders, treatment of rare and orphan diseases, and treatment of neurological diseases and disorders

Pharmaceutical, medical, scientific, and biopharmaceutical research and development; Scientific research, pharmaceutical research, and medical research; Technology consultation and scientific research consultation both provided in the fields of biotechnology and development of pharmaceuticals; Product development for others in the fields of biotechnology and development of pharmaceuticals
remaster

General Information


Serial Number98941335
Word MarkREMASTER
Filing DateTuesday, January 7, 2025
Status661 - RESPONSE AFTER NON-FINAL ACTION - ENTERED
Status DateTuesday, September 9, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesPharmaceutical preparations and therapeutic pharmaceutical preparations both for the treatment of cancer, treatment of immune system related diseases and disorders, treatment of cardiovascular diseases and disorders, treatment of genetic diseases and disorders, treatment of rare and orphan diseases, and treatment of neurological diseases and disorders
Goods and ServicesPharmaceutical, medical, scientific, and biopharmaceutical research and development; Scientific research, pharmaceutical research, and medical research; Technology consultation and scientific research consultation both provided in the fields of biotechnology and development of pharmaceuticals; Product development for others in the fields of biotechnology and development of pharmaceuticals

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, January 7, 2025
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, January 7, 2025
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameRemix Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressWatertown, MA 02472

Trademark Events


Event DateEvent Description
Tuesday, January 7, 2025NEW APPLICATION ENTERED
Tuesday, April 29, 2025NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, August 1, 2025NON-FINAL ACTION E-MAILED
Friday, August 1, 2025NON-FINAL ACTION WRITTEN
Friday, August 1, 2025NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, September 9, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, September 9, 2025TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, September 9, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, June 16, 2025ASSIGNED TO EXAMINER